Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Telix Pharmaceuticals ( (AU:TLX) ) is now available.
Telix Pharmaceuticals Limited is hosting an Investor Day event in New York City, which will be a hybrid event allowing both in-person and virtual participation. This event is significant for stakeholders as it provides an opportunity for institutional investors and analysts to engage with the company, potentially impacting Telix’s market positioning and investor relations.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$26.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals Limited is a biopharmaceutical company specializing in the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. The company is headquartered in Melbourne, Australia, and operates internationally in the United States, Brazil, Canada, Europe, and Japan. Telix focuses on addressing significant unmet medical needs in oncology and rare diseases.
Average Trading Volume: 1,601,190
Technical Sentiment Signal: Buy
Current Market Cap: A$8.79B
For a thorough assessment of TLX stock, go to TipRanks’ Stock Analysis page.